Are there any studies of KLOW's side effects?
No. KLOW is a supplier-defined blend and no study has evaluated the four peptides together. Everything on this page is inferred from data on the individual components.
Copper-Peptide Matrix, Regenerative & Anti-Inflammatory Stack
KLOW — GHK-Cu + BPC-157 + TB-500 + KPV Four-Peptide Blend
Last reviewed: September 2026
KLOW is a Purgo Labs blend of four research peptides in one vial: GHK-Cu (a copper peptide used in skin research), BPC-157 and TB-500 (two animal-studied healing peptides), and KPV (a small anti-inflammatory peptide). It is the Glow Complex with KPV added.
Each part targets a different step of tissue repair: GHK-Cu rebuilds the collagen matrix, BPC-157 grows blood supply, TB-500 moves repair cells into place, and KPV turns down inflammatory signals.
For researchers studying skin, wound or connective-tissue models, a single vial covering four pathways is convenient — provided the fixed ratio suits the experiment.
No study has tested these four together. GHK-Cu has good evidence in skin biology; the other three are animal-study peptides. KLOW is not a hormonal or weight-loss product. Research-only.
KLOW is Purgo Labs' four-peptide research blend: 50mg GHK-Cu, 10mg BPC-157, 10mg TB-500 and 10mg KPV co-lyophilized in a single 80mg vial. It is the Glow Complex (GHK-Cu + BPC-157 + TB-500) with the anti-inflammatory tripeptide KPV added — the "K" in the name. The rationale is a skin- and tissue-repair stack: copper-peptide matrix remodelling from GHK-Cu, angiogenic and cytoprotective signalling from BPC-157, actin-regulated cell migration from TB-500, and NF-κB-mediated cytokine suppression from KPV.
Each component has its own literature — GHK-Cu the deepest, BPC-157 and thymosin-β4 substantial in animals, KPV in mouse colitis — but no study has tested the four together. Everything said about KLOW as a blend is inference from the parts. (Correction, 10 September 2026: an earlier version of this page described KLOW as kisspeptin-10, which is a different Purgo product; see the Kisspeptin page.)
Per 3 mL vial: GHK-Cu 50mg (glycyl-histidyl-lysine copper(II) complex, 403.9 Da), BPC-157 10mg (15-residue gastric pentadecapeptide, 1,419.5 Da), TB-500 10mg (synthetic thymosin-β4 actin-binding fragment, ~889 Da) and KPV 10mg (Lys-Pro-Val, 342.4 Da); 80mg total, lyophilized as one formula. GHK-Cu dominates the mass at 62.5%. Purgo screens the blend as a full formula for purity and identity with a third-party certificate; researchers who need per-component quantitation should request the certificate before use.
KLOW stacks four repair-pathway peptides — GHK-Cu for matrix rebuilding, BPC-157 for blood supply, TB-500 for cell migration and KPV for inflammation control — in one 80mg vial; each is studied alone, none together.
The four peptides act through non-overlapping pathways. GHK-Cu delivers copper to the extracellular matrix and modulates several thousand genes, up-regulating collagen, elastin, decorin and antioxidant enzymes while down-regulating inflammatory signalling. BPC-157 promotes angiogenesis via VEGFR2 and nitric-oxide pathways and stabilises the epithelial barrier and gut–brain axis in animal models. TB-500 sequesters G-actin and drives keratinocyte, endothelial and fibroblast migration into wounds, lowering inflammation and scarring. KPV enters cells through the PepT1 transporter and inhibits NF-κB, suppressing TNF-α, IL-6 and IL-1β.
The blend hypothesis is additive rather than synergistic: matrix rebuilding (GHK-Cu), blood supply (BPC-157), cell migration (TB-500) and inflammation control (KPV) address different phases of tissue repair. Pharmacokinetic interaction between the peptides has not been studied, and the doses fixed by the blend ratio (5:1:1:1) may not match the ratios used in any single-agent study.
Copper delivery and gene-expression shifts increase collagen, elastin and decorin synthesis and antioxidant enzyme activity.
VEGFR2 and NO-pathway activation improve vascular supply to injured tissue in animal models.
G-actin sequestration accelerates keratinocyte, endothelial and fibroblast migration into wound sites.
PepT1-mediated uptake and NF-κB inhibition lower TNF-α, IL-6 and IL-1β at the site of inflammation.
Each outcome rated by the highest level of evidence available. Tiers follow our 5-tier methodology.
Study counts reflect peer-reviewed publications in the evidence database below. "Theoretical" outcomes have mechanistic rationale only. Learn about our evidence tiers →
Peer-reviewed literature supporting the research profile of KLOW
The following peer-reviewed studies form the primary evidence base for KLOW's research profile. All references are sourced from PubMed, NCBI, and peer-reviewed scientific journals. Published research is available through PubMed, NCBI, and peer-reviewed biomedical journals.
Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences. 2018.PMID: 29986520
GHK-Cu resets gene expression toward regeneration: collagen, elastin and antioxidant genes up, inflammatory and fibrotic genes down.
Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011.PMID: 21548867
Review of BPC-157's cytoprotective, angiogenic and healing effects across rodent injury models.
Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005.PMID: 16099219
Thymosin-β4 promotes dermal and corneal wound healing via cell migration and anti-inflammatory effects.
Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008.PMID: 18061177
KPV reduced colitis in mice after transporter-mediated uptake into epithelial and immune cells.
Blends Research
Purgo Labs list price, read 12 Sep 2026 · per-lot COA on the vendor page
Use code HEALTH for 20% off
Fast FedEx shipping · Discreet packaging
View full legal status guide →
Source KLOW at Purgo Labs
≥99% purity · Third-party COA · Use code HEALTH for 30% off
Supplier-defined four-peptide blend (GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg, KPV 10mg per 80mg vial) — no study has evaluated the combination; everything below is inferred from the components
KLOW is a four-peptide research blend. No study has evaluated the combination. What follows is the known and unknown safety picture for each part, and nothing invented to fill the gaps. KLOW is not approved for human use anywhere, and none of its components has a controlled human safety trial by injection.
Research-use information only. Research-grade KLOW is not an approved medicine; where trial or label figures appear below they belong to the pharmaceutical product studied, not to any research vial. This section does not give dosing or medical advice.
Every rate carries its source. Where no source exists, no rate is printed.
| Effect | Rate (sourced) | Detail | Source |
|---|---|---|---|
| GHK-Cu (50mg): injection-site irritation, copper load | not quantified | The best-characterised component. Topical GHK-Cu has been used in human skin studies for decades with a benign tolerability record. Injectable use is far less studied; the copper load matters — 50mg of GHK-Cu carries roughly 8mg of copper — and site irritation is the most commonly reported issue in informal reports. | — |
| BPC-157 (10mg): regulatory flag, not a safety finding | not quantified | Rodent studies report few adverse findings, and a small number of early human tolerability reports exist. In September 2023 the FDA placed BPC-157 in Category 2 of its bulk-substances evaluation, citing insufficient safety data (not evidence of harm). | — |
| TB-500 (10mg): parent peptide tolerated in trials, fragment unstudied | not quantified | TB-500 is a synthetic fragment of thymosin-β4. Full-length thymosin-β4 has been through human trials (cardiac and corneal) with an acceptable safety profile; the fragment itself has no human data. | — |
| KPV (10mg): no adverse signal in rodent colitis models | not quantified | A three-amino-acid fragment of α-MSH. Rodent colitis studies report no adverse signals; KPV lacks α-MSH's pigmentary effect. | — |
No study has evaluated this combination. The evidence lives with the components:
Regulatory status: Not approved for human use anywhere. Research use only.
No. KLOW is a supplier-defined blend and no study has evaluated the four peptides together. Everything on this page is inferred from data on the individual components.
For any injected research peptide: injection-site redness, swelling or pain, and the possibility of hypersensitivity reactions. Specific to KLOW, the 50mg GHK-Cu component is the one with a plausible dose-related concern (copper load and site irritation).
No. An earlier version of this page wrongly described KLOW as kisspeptin-10. Kisspeptin is a separate Purgo product with its own profile; KLOW is GHK-Cu + BPC-157 + TB-500 + KPV.
Yes. The blend is 5:1:1:1 by mass. Reconstituting to reach a literature-typical amount of one component fixes the amount of the other three — most notably, dosing BPC-157 or TB-500 to common research amounts means a large GHK-Cu dose alongside.
Side-effect section last reviewed 2026-09-10. Moved from the standalone side-effects page on 10 October 2026; text unchanged.
Each KLOW component has independent evidence — GHK-Cu in human skin and gene-expression studies; BPC-157, TB-500 and KPV in animal and cell models. No study has evaluated the four-peptide blend.
Purgo Labs offers KLOW with ≥99% purity, third-party certificates of analysis, and fast FedEx shipping. This is an affiliate link — we may earn a commission at no cost to you.